Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antilipidemic pharmaceutical compositions and process for preparation thereof

A technology of blood lipid-lowering drugs and compositions, applied in the field of oral pharmaceutical compositions, capable of solving problems such as reduced compliance

Inactive Publication Date: 2009-12-02
RANBAXY LAB LTD
View PDF11 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] Moreover, the study found that as the number of prescribed medications increased, patient compliance with those medications decreased

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antilipidemic pharmaceutical compositions and process for preparation thereof
  • Antilipidemic pharmaceutical compositions and process for preparation thereof
  • Antilipidemic pharmaceutical compositions and process for preparation thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] Particle I:

[0106] Preparation of Fenofibrate Granules I

[0107] composition

[0108]

[0109] step:

[0110] 1. Dissolve fenofibrate, polyvinylpyrrolidone and sodium lauryl sulfate in water and stir to form a clear solution.

[0111] 2. A mixture of acetone:dichloromethane (70:30 ratio) was added to the solution from step 1 while stirring and stirring was continued for 45 minutes.

[0112] 3. Spray the solution from step 2 onto the mixture of pregelatinized starch and lactose to form fenofibrate granules.

[0113] 4. The dried granules of step 3 were sieved and mixed with cross-linked polyvinylpyrrolidone, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate to form a fenofibrate granule mixture.

Embodiment 2

[0115] Particle II:

[0116] Preparation of Fenofibrate Granules II

[0117] composition

[0118]

[0119] step:

[0120] 1. Dissolve fenofibrate, polyvinylpyrrolidone, and docusate sodium in isopropanol and stir to form a clear solution.

[0121] 2. Spray the solution from step 1 onto the mixture of microcrystalline cellulose, sodium lauryl sulfate and red iron oxide to form fenofibrate granules.

[0122] 3. The dried granules from step 2 were sieved and blended with cross-linked polyvinylpyrrolidone, microcrystalline cellulose, colloidal silicon dioxide and magnesium stearate to form a fenofibrate granule mixture.

[0123] Particle III:

[0124] Preparation of Ezetimibe Granules

[0125] composition

[0126]

[0127]

[0128] step:

[0129] 1. Mix ezetimibe, croscarmellose sodium and lactose together to form a homogeneous mixture.

[0130] 2. Sodium lauryl sulfate and polyvinylpyrrolidone were dissolved in water and mixed with the mixture of step 1 to form e...

Embodiment 3

[0162] The fenofibrate granules of Example 1 were compressed with a special tool to form a monolithic tablet. The tablets were coated with the coating composition described above.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a new process for preparing an oral pharmaceutical composition comprising fenofibrate alone or in combination with at least one other antilipidemic agent in a single dosage form that can be conveniently administered once or twice in a day.

Description

field of invention [0001] The present invention relates to a new process for the preparation of oral pharmaceutical compositions comprising fenofibrate alone or in combination with at least one hypolipidemic drug in a single dosage form, which can be conveniently administered once a day or Two doses. Background of the invention [0002] In the human body, cholesterol and triglyceride (TG) are components of lipoprotein complexes in the blood stream, which can be separated by ultracentrifugation to form high-density lipoprotein (HDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein ( LDL) and very low-density lipoprotein (VLDL) fractions. Cholesterol and triglycerides are synthesized in the liver, incorporated into VLDL and released into the blood. High levels of total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apo-B, the membrane complex of LDL-C) induce human atherosclerosis, and HDL- Decreased levels of C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/16A61K9/50A61K31/216
Inventor S·马丹R·辛格P·太吉V·K·阿罗拉
Owner RANBAXY LAB LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com